Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR2 | O95136 | 14/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3315118 | 0.94 | S1PR2 (0.74) | S1PR2ALDH1A1SMN1; SMN2MEN1TSHR | |
| SCHEMBL14068491 | 0.89 | S1PR2 (0.71) | S1PR2ALDH1A1SMN1; SMN2TSHRKMT2A | |
| SCHEMBL14068349 | 0.89 | S1PR2 (0.73) | S1PR2ALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL3312182 | 0.85 | S1PR2 (0.68) | S1PR2ALDH1A1SMN1; SMN2MEN1TSHR | |
| SCHEMBL14068487 | 0.85 | S1PR2 (0.75) | S1PR2MAPT | |
| SCHEMBL14068366 | 0.85 | S1PR2 (0.70) | S1PR2ALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL14068357 | 0.83 | S1PR2 (0.61) | S1PR2ALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL14068488 | 0.83 | ALDH1A1 (0.65) | S1PR2ALDH1A1SMN1; SMN2HSD17B10 | |
| SCHEMBL3312852 | 0.83 | S1PR2 (0.80) | S1PR2SMN1; SMN2TSHRKMT2A | |
| SCHEMBL14068353 | 0.83 | S1PR2 (0.71) | S1PR2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008107436-A1 | BICYCLIC ORGANIC COMPOUNDS SUITABLE FOR THE TREATMENT OF INFLAMMATORY OR ALLERGIC CONDITIONS | NOVARTIS AG (CH) | 2008-09-12 | — | — | WO | disclosed |